13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001697013
Total reported value
$1.9B
$1.9B
65 檔
26.4%
In Q4 2024, Eversept Partners, LP's U.S. equity holdings reached a combined market value of $1.9B, distributed across 65 disclosed stock positions.
In Q4 2024, Eversept Partners, LP adopted a defensive or profit-taking posture, trimming 31 positions and completely liquidating 17 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | Stock-Healthcare | 12.32% | -1.58% | +0.76% | |
| 2 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 11.03% | -3.49% | -2.60% | |
| 3 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 10.99% | -3.89% | -9.75% | |
| 4 | VERA | Vera Therapeutics Inc | Stock-Other | 6.01% | +0.32% | -21.96% | |
| 5 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 4.84% | — | +6.53% | |
| 6 | HCA | Hca Healthcare Inc | Stock-Healthcare | 4.68% | +0.01% | +36.20% | |
| 7 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 4.39% | — | -30.68% | |
| 8 | RVTY | Revvity Inc | Stock-Healthcare | 3.89% | +0.09% | -16.43% | |
| 9 | HQY | Healthequity Inc | Stock-Healthcare | 3.29% | -0.23% | EXIT | |
| 10 | ZIMV | Zimvie Inc | Stock-Other | 2.56% | — | — | |
| 11 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.33% | +0.37% | NEW | |
| 12 | TECH | Bio-techne CORP | Stock-Healthcare | 1.91% | -0.28% | -54.89% | |
| 13 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.61% | +0.46% | +27.43% | |
| 14 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 1.55% | -3.67% | EXIT | |
| 15 | VTRS | Viatris Inc | Stock-Healthcare | 1.41% | — | -26.31% | |
| 16 | TLT | Ishares 20+ Year Treasury Bd | ETF-Gov Bonds | 1.39% | -1.96% | EXIT | |
| 17 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.37% | -0.17% | -66.63% | |
| 18 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.33% | +0.05% | +12.84% | |
| 19 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.32% | -0.56% | +269.87% | |
| 20 | BRKR | Bruker CORP | Stock-Healthcare | 1.22% | +0.35% | — | |
| 21 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.12% | — | — | |
| 22 | DXCM | Dexcom Inc | Stock-Healthcare | 1.03% | — | — | |
| 23 | CNC | Centene CORP | Stock-Healthcare | 1.01% | -0.19% | EXIT | |
| 24 | TFX | Teleflex Inc | Stock-Healthcare | 0.98% | — | — | |
| 25 | ELV | Elevance Health Inc | Stock-Healthcare | 0.96% | — | +49.90% | |
| 26 | PCVX | Vaxcyte Inc | Stock-Other | 0.93% | -0.93% | — | |
| 27 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.76% | +1.50% | -43.64% | |
| 28 | CYH | Community Health Systems Inc | Stock-Other | 0.75% | +0.01% | -67.79% | |
| 29 | GH | Guardant Health Inc | Stock-Healthcare | 0.75% | — | — | |
| 30 | RGEN | Repligen CORP | Stock-Healthcare | 0.69% | -0.65% | -66.95% | |
| 31 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.67% | +0.23% | -54.40% | |
| 32 | FTRE | Fortrea Holdings Inc | Stock-Healthcare | 0.67% | — | -12.28% | |
| 33 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.63% | — | -10.41% | |
| 34 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 0.60% | — | — | |
| 35 | LQDA | Liquidia CORP | Stock-Other | 0.60% | +0.42% | +314.14% | |
| 36 | MEDP | Medpace Holdings Inc | Stock-Healthcare | 0.56% | — | — | |
| 37 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.54% | +0.22% | — | |
| 38 | MNKD | Mannkind CORP | Stock-Other | 0.52% | — | -54.28% | |
| 39 | HUM | Humana Inc | Stock-Healthcare | 0.51% | +0.64% | NEW | |
| 40 | HSIC | Henry Schein Inc | Stock-Healthcare | 0.49% | — | — | |
| 41 | DHR | Danaher CORP | Stock-Healthcare | 0.45% | — | -42.21% | |
| 42 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.40% | -0.38% | -91.64% | |
| 43 | PDCOEUR | Patterson Cos Inc | Stock-Other | 0.40% | — | — | |
| 44 | GOSS | Gossamer Bio Inc | Stock-Other | 0.40% | — | — | |
| 45 | EOLS | Evolus Inc | Stock-Other | 0.38% | — | -15.45% | |
| 46 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.36% | -0.40% | EXIT | |
| 47 | SUPN | Supernus Pharmaceuticals Inc | Stock-Healthcare | 0.34% | — | — | |
| 48 | AVTR | Avantor Inc | Stock-Healthcare | 0.31% | -1.23% | EXIT | |
| 49 | PBYI | Puma Biotechnology Inc | Stock-Other | 0.27% | — | -22.98% | |
| 50 | TSVT* | 2seventy Bio Inc | Stock-Other | 0.26% | — | +0.56% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | +4.8% | +0.76% | Add |
| 2 | QQQ | Invesco Qqq Trust Series 1 | +2.7% | -2.60% | Trim |
| 3 | HQY | Healthequity Inc | +1.5% | +21.19% | Add |
| 4 | TLT | Ishares 20+ Year Treasury Bd | +1.4% | NEW | New buy |
| 5 | BRKR | Bruker CORP | +1.2% | NEW | New buy |
| 6 | EW | Edwards Lifesciences CORP | +1.1% | NEW | New buy |
| 7 | HCA | Hca Healthcare Inc | +1.1% | +36.20% | Add |
| 8 | BCRX | Biocryst Pharmaceuticals Inc | +1% | +269.87% | Add |
| 9 | DXCM | Dexcom Inc | +1% | NEW | New buy |
| 10 | TFX | Teleflex Inc | +1% | NEW | New buy |
| 11 | PTGX | Protagonist Therapeutics Inc | +1% | +52.47% | Add |
| 12 | PCVX | Vaxcyte Inc | +0.9% | NEW | New buy |
| 13 | INSP | Inspire Medical Systems Inc | +0.9% | +6.53% | Add |
| 14 | GH | Guardant Health Inc | +0.8% | NEW | New buy |
| 15 | AZNN | Astrazeneca Plc-spons Adr | +0.6% | NEW | New buy |
| 16 | MEDP | Medpace Holdings Inc | +0.6% | NEW | New buy |
| 17 | XENE | Xenon Pharmaceuticals Inc | +0.5% | NEW | New buy |
| 18 | LQDA | Liquidia CORP | +0.5% | +314.14% | Add |
| 19 | HSIC | Henry Schein Inc | +0.5% | NEW | New buy |
| 20 | TEVA | Teva Pharmaceutical-sp Adr | +0.4% | -30.68% | Trim |
| 21 | PDCOEUR | Patterson Cos Inc | +0.4% | NEW | New buy |
| 22 | SUPN | Supernus Pharmaceuticals Inc | +0.3% | NEW | New buy |
| 23 | ZIMV | Zimvie Inc | +0.3% | — | Unchanged |
| 24 | CNC | Centene CORP | +0.3% | +39.67% | Add |
| 25 | CLDX | Celldex Therapeutics Inc | +0.3% | +27.43% | Add |
| 26 | NAMS | NewAmsterdam Pharma Company N.V. | +0.3% | -10.41% | Trim |
| 27 | ELV | Elevance Health Inc | +0.3% | +49.90% | Add |
| 28 | VRDN | Viridian Therapeutics Inc | +0.3% | +12.84% | Add |
| 29 | XRAY | Dentsply Sirona Inc | +0.2% | NEW | New buy |
| 30 | 2662247D | Iteos Therapeutics Inc | +0.2% | NEW | New buy |
| 31 | ICLR | ICON Public Limited Company | +0.1% | +40.85% | Add |
| 32 | GOSS | Gossamer Bio Inc | +0.1% | — | Unchanged |
| 33 | XOMA | Xoma Royalty Corporation | +0.1% | +1.20% | Add |
| 34 | VTRS | Viatris Inc | 0% | -26.31% | Trim |
| 35 | FTRE | Fortrea Holdings Inc | 0% | -12.28% | Trim |
| 36 | PBYI | Puma Biotechnology Inc | 0% | -22.98% | Trim |
| 37 | ZLAB | Zai Lab Ltd-adr | 0% | -23.88% | Trim |
| 38 | ✓ | Merus N V | 0% | — | Unchanged |
| 39 | MREO | Mereo Biopharma Group Pl-adr | 0% | — | Unchanged |
| 40 | AVTR | Avantor Inc | 0% | — | Unchanged |
| 41 | ABSI | Absci CORP | 0% | -26.90% | Trim |
| 42 | ACIU | AC Immune SA | 0% | EXIT | Sold out |
| 43 | STOK | Stoke Therapeutics Inc | 0% | EXIT | Sold out |
| 44 | ✓ | Affimed N V | 0% | EXIT | Sold out |
| 45 | TSVT* | 2seventy Bio Inc | -0.1% | +0.56% | Add |
| 46 | IFRX | InflaRx N.V. | -0.1% | -69.64% | Trim |
| 47 | TVTX | Travere Therapeutics Inc | -0.1% | -43.64% | Trim |
| 48 | ✓ | Amarin Corp PLC | -0.1% | -54.17% | Trim |
| 49 | ✓ | -0.1% | EXIT | Sold out | |
| 50 | AUTL | Autolus Therapeutics PLC | -0.1% | -75.68% | Trim |
According to official SEC Form 13F filings, Eversept Partners, LP reported a total U.S. public equity portfolio value of $1.9B across 65 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NTRA, QQQ, GSK) accounted for 26.4% of total reported equity market value during Q4 2024.
Top New Position Initiated
TLT
市值: $15.7M
Top Position Liquidated / Trimmed
INSM
前期市值: $79.5M
During Q4 2024, Eversept Partners, LP's top holdings by market value included NTRA (12.3%)、QQQ (11.0%)、GSK (11.0%). The largest single position, NTRA, represented 12.3% of total portfolio value.
In Q4 2024, Eversept Partners, LP made 77 total portfolio adjustments, initiating 15 new buys, adding to 14 positions, trimming 31 holdings, and fully liquidating 17 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.